Sa1753 - Tofacitinib Achieves Symptomatic Improvement within 3 Days in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior Tumour Necrosis Factor Inhibitor Treatment Status: Results from Octave Induction 1 & 2

Active Ulcerative Colitis ◽

Treatment Status ◽

Factor Inhibitor ◽

Necrosis Factor ◽

DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx180.061 ◽

2018 ◽

Vol 12 (supplement_1) ◽

pp. S046-S048 ◽

Cited By ~ 2

Author(s):

S Hanauer ◽

R Panaccione ◽

S Danese ◽

A Cheifetz ◽

W Reinisch ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Symptomatic Improvement ◽

Active Ulcerative Colitis ◽

Treatment Status ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Tumour necrosis factor inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients

10.1136/ard.2002.004226 ◽

2004 ◽

Vol 63 (3) ◽

pp. 318-320 ◽

Cited By ~ 77

Author(s):

C Pritchard

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis

Modern Rheumatology Case Reports ◽

10.1080/24725625.2020.1800958 ◽

2020 ◽

Vol 5 (1) ◽

pp. 156-161

Author(s):

Akitsu Yoshida ◽

Yasuhiro Katsumata ◽

Shinya Hirahara ◽

Masanori Hanaoka ◽

Moeko Ochiai ◽

...

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Factor Inhibitor ◽

Necrosis Factor

Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment

British Journal of Dermatology ◽

10.1111/bjd.18869 ◽

2020 ◽

Vol 183 (1) ◽

pp. 7-8

Author(s):

T.‐F. Tsai

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry

10.1136/annrheumdis-2015-208490 ◽

2015 ◽

Vol 75 (4) ◽

pp. 785-786 ◽

Cited By ~ 18

Author(s):

L Dreyer ◽

M Magyari ◽

B Laursen ◽

R Cordtz ◽

F Sellebjerg ◽

...

Keyword(s):

Multiple Sclerosis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Population Based ◽

Population Based Study ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry

10.1136/annrheumdis-2012-201319 ◽

2012 ◽

Vol 72 (1) ◽

pp. 57-63 ◽

Cited By ~ 23

Author(s):

Lykke Midtbøll Ørnbjerg ◽

Mikkel Østergaard ◽

Pernille Bøyesen ◽

Niels Steen Krogh ◽

Anja Thormann ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Practice ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Radiographic Progression ◽

Factor Inhibitor ◽

Necrosis Factor ◽

No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment

10.1136/annrheumdis-2014-205622 ◽

2014 ◽

Vol 73 (11) ◽

pp. 2061-2062 ◽

Cited By ~ 1

Author(s):

Elizabeth V Arkema ◽

Nils Feltelius ◽

Tomas Olsson ◽

Johan Askling

Keyword(s):

Rheumatoid Arthritis ◽

Amyotrophic Lateral Sclerosis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Lateral Sclerosis ◽

OP0261 RISK OF NEUROLOGICAL ADVERSE EVENTS DURING TUMOUR NECROSIS FACTOR INHIBITOR TREATMENT FOR ARTHRITIS: A POPULATION-BASED COHORT STUDY FROM DANBIO AND ARTIS

10.1136/annrheumdis-2019-eular.1747 ◽

2019 ◽

Author(s):

Tine Iskov Kopp ◽

Elizabeth Arkema ◽

René Cordtz ◽

Bénédicte Delcoigne ◽

Johan Askling ◽

...

Keyword(s):

Cohort Study ◽

Adverse Events ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Population Based ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

Scandinavian Journal of Rheumatology ◽

10.1080/03009742.2021.1967046 ◽

2021 ◽

pp. 1-7

Author(s):

T Rusman ◽

MT Nurmohamed ◽

S Hoekstra ◽

CJ van Denderen ◽

RF van Vollenhoven ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Observational Study ◽

Disease Activity ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Factor Inhibitor ◽

Necrosis Factor ◽

Faculty Opinions recommendation of Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108991.565450 ◽

2008 ◽

Author(s):

Martin Aringer ◽

Alexander Kleymann

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Joint Damage ◽

Inadequate Response ◽

Structural Joint ◽

Factor Inhibitor ◽

Necrosis Factor